Program
Valsartan
Also written as “valsartan”, “sacubitril/valsartan” and “valsartan plus hydrochlorothiazide”.
Its studies are mostly in Hypertension · Essential Hypertension · Heart Failure · Diabetes Mellitus, Type 2 · Proteinuria, led by 14 companies.
Drug pageValsartan: every studyMany companies study it; this page follows only the 125 they lead. All 254 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartisits history only | 1060 open or running | phase 4since Sep 10, 2005 | Nov 30, 2004 | none ahead |
| LG Chemits history only | 50 open or running | phase 3since Aug 5, 2013 | May 11, 2010 | none ahead |
| IlDong Pharmaceuticalits history only | 20 open or running | phase 3since May 20, 2014 | May 20, 2014 | none ahead |
| Sun Pharmaceutical Industriesits history only | 20 open or running | no phasesince Jul 21, 2014 | Jul 21, 2014 | none ahead |
| ARKAY Therapeuticsits history only | 10 open or running | phase 2since Sep 23, 2018 | Sep 23, 2018 | none ahead |
| Dexa Medica Groupits history only | 10 open or running | no phasesince Aug 3, 2015 | Aug 3, 2015 | none ahead |
| EMSits history only | 10 open or running | phase 3since Nov 23, 2015 | Nov 23, 2015 | none ahead |
| Farma de Colombia | 10 open or running | phase 3since May 7, 2013 | May 7, 2013 | none ahead |
| Genuine Research Center, Egyptits history only | 10 open or running | phase 1since Jul 30, 2015 | Jul 30, 2015 | none ahead |
| Hanlim Pharm.its history only | 10 open or running | phase 1since Aug 2, 2018 | Aug 2, 2018 | none ahead |
| JW Pharmaceuticalits history only | 10 open or running | phase 1since Jul 26, 2011 | Jul 26, 2011 | none ahead |
| Lunan Pharmaceutical Groupits history only | 11 open or running | phase 3since Mar 4, 2025 | Mar 4, 2025 | Dec 2027phase 3 · NCT06863987 |
| TSH Biopharmits history only | 10 open or running | phase 4since Feb 4, 2014 | Feb 4, 2014 | none ahead |
| Yuhanits history only | 10 open or running | phase 1since Jan 5, 2012 | Jan 5, 2012 | none ahead |
Also a collaborator on its studies: Bristol-Myers Squibb, GlaxoSmithKline and Bayer.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Farma de Colombia only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 7, 2013First study: phase 3 study in HypertensionFirst studyNCT01850160 · 124 enrolled · Colombia, Ecuador
TargetBeta
“Type-1 angiotensin II receptor antagonist”ChEMBL 37, by rule
Other programs on AGTR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Telmisartanrule | Boehringer Ingelheim | phase 4 | 132 |
| Losartanrule | Organon | phase 4 | 58 |
| azilsartan medoxomilrule | Takeda | phase 4 | 25 |
| sparsentanrule | travere-therapeutics-inc | phase 4 | 9 |
Studies
The one study Farma de Colombia leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01850160Hypertension · Colombia, Ecuador | 3 | Completed | Mar 2015 | 124 |
How it is read
Names in the registry
- “Valsartan”, 31 entries
- “valsartan”, 23 entries
- “sacubitril/valsartan”, 5 entries
- “valsartan plus hydrochlorothiazide”, 5 entries
- “valsartan + amlodipine”, 5 entries
Conditions, from the studies’ own filings
- Hypertension, 98 studies
- Essential Hypertension, 10 studies
- Heart Failure, 8 studies
- Diabetes Mellitus, Type 2, 5 studies
- Proteinuria, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.